Generally, RABBIT shows biologic DMARDs to be effective, safe and well tolerated in daily rheumatologic care. Used by experienced rheumatologists, they are a safe treatment option for patients with rheumatoid arthritis, who do not respond adequately to non-biologic DMARDs.
In practice, biologic DMARDs are not prescribed until non-biologic DMARDs fail or are not tolerated. That means that patients for whom biologic DMARDs are indicated differ systematically from patients who are treated with non-biologic DMARDs. Therefore, highly sophisticated statistical methods are required to compare patients on biologic and non-biologic DMARDs.
Here, we will give a short insight into our published results: Original publications
| Eingeschlossene Patienten: 22.457 (Stand 01. November 2023) | |
|---|---|
| Amgevita® (Adalimumab) | 202 |
| Benepali® (Etanercept) | 1141 |
| Cimzia® (Certolizumab) | 1019 |
| Enbrel® (Etanercept) | 2872 |
| Erelzi® (Etanercept) | 491 |
| Flixabi® (Infliximab) | 10 |
| Hulio® (Adalimumab) | 221 |
| Humira® (Adalimumab) | 2908 |
| Hyrimoz® (Adalimumab) | 193 |
| Idacio® (Adalimumab) | 59 |
| Imraldi® (Adalimumab) | 192 |
| Inflectra™ (Infliximab) | 16 |
| Jyseleca® (Filgotinib) | 118 |
| Kevzara® (Sarilumab) | 207 |
| Kineret® (Anakinra) | 89 |
| MabThera® (Rituximab) | 1459 |
| Nepexto® (Etanercept) | 57 |
| Olumiant® (Baricitinib) | 527 |
| Orencia® (Abatacept) | 967 |
| Remicade® (Infliximab) | 762 |
| Remsima® (Infliximab) | 19 |
| Rinvoq® (Upadacitinib) | 289 |
| Rixathon® (Rituximab) | 20 |
| RoActemra® (Tocilizumab) | 1371 |
| Ruxience® (Rituximab) | 1 |
| Simponi® (Golimumab) | 466 |
| Xeljanz® (Tofacitinib) | 394 |
| Yuflyma® (Adalimumab) | 15 |
| Zessly® (Infliximab) | 2 |
| Kontrollen | 6370 |
